Analysis of CYP2C9*2,CYP2C9*3 and VKORC1 ‐1639 G>A polymorphisms in a population from South‐Eastern Europe
Open Access
- 13 December 2012
- journal article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 16 (12), 2919-2924
- https://doi.org/10.1111/j.1582-4934.2012.01606.x
Abstract
The CYP2C9 enzyme metabolizes a wide range of relevant drugs, among which are oral anticoagulants. VKORC1 is the pharmacodynamic target of the oral anticoagulants. The genetic polymorphisms CYP2C9*2, CYP2C9*3 and VKORC1 -1639 G>A are the major determinants of the inter-individual variability in the dosage requirements of oral anticoagulants. This study provides a first evaluation of these 3 polymorphisms in a Romanian population. A total of 332 Romanian individuals were genotyped for the CYP2C9*2, CYP2C9*3 and VKORC1 -1639 G>A polymorphisms using the PCR-RFLP technique. Sixty-two individuals (18.7%) were heterozygous for CYP2C9*2, whereas 47 individuals (14.1%) were heterozygous for CYP2C9*3. Fourteen individuals (4.2%) had a CYP2C9*2 homozygous, CYP2C9*3 homozygous or CYP2C9*2/CYP2C9*3 compound heterozygous genotype. These individuals are predicted to have the lowest CYP2C9 enzymatic activity. The allele frequencies of the CYP2C9*2 and CYP2C9*3 polymorphisms were 11.3% and 9.3% respectively. For the VKORC1 -1639 G>A polymorphism, there were 170 heterozygotes (51.2%) and 55 (16.6%) homozygotes for the A allele. The frequency of the A allele was 42.2%. Overall, the distribution of the CYP2C9*2, CYP2C9*3 and VKORC1 -1639 G>A polymorphisms observed in our cohort is in accordance with other Caucasian populations. A large number of Romanians are expected to harbour at least one CYP2C9 variant allele and/or one VKORC1 -1639 G>A allele. This frequency has major implications in the pharmacogenomics of oral anticoagulants in Romanians.Keywords
This publication has 34 references indexed in Scilit:
- Genetic variants in CYP ( -1A2 , -2C9 , -2C19 , -3A4 and -3A5 ), VKORC1 and ABCB1 genes in a black South African population: a window into diversityPharmacogenomics, 2011
- Pharmacogenetics of Coumarin Dosing: Prevalence of CYP2C9 and VKORC1 Polymorphisms in the Lebanese PopulationGenetic Testing and Molecular Biomarkers, 2011
- Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin DosingClinical Pharmacology & Therapeutics, 2011
- Interethnic differences of CYP2C9 alleles in healthy Hungarian and Roma population samples: Relationship to worldwide allelic frequenciesBlood Cells, Molecules, and Diseases, 2009
- Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical PracticePharmacological Reviews, 2006
- CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian populationFundamental & Clinical Pharmacology, 2004
- Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic PolymorphismsThe Journal of Clinical Pharmacology, 2004
- Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian populationPharmacological Research, 2004
- Genetic polymorphisms ofCYP2C9andCYP2C19in the Beninese and Belgian populationsBritish Journal of Clinical Pharmacology, 2003
- Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populationsFundamental & Clinical Pharmacology, 2003